Understanding how second primary malignancies arise following multiple myeloma therapy

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1124979

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Multiple myeloma is a cancer of white blood cells. Chemotherapy and new drugs that target cancer cells are the most effective therapies for multiple myeloma. However, these drugs also increase the chance of developing a secondary cancer that is different to the initial cancer. Little is known about how these cancers arise. I aim to find out how current therapies cause secondary cancers; with the hope of finding alternative therapies for multiple myeloma that do not cause secondary cancers.

Funded Activity Details

Start Date: 01-01-2017

End Date: 01-01-2020

Funding Scheme: Early Career Fellowships

Funding Amount: $408,768.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Haematological Tumours

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

DNA adducts | chemotherapy treatment effects | haematological malignancy | multiple myeloma | ubiquitination

Related Links